Impact of Prior Authorization on the Use and Costs of Lipid-Lowering Medications Among Michigan and Indiana Dual Enrollees in Medicaid and Medicare: Results of a Longitudinal, Population-Based Study

Clinical Therapeutics

Volumn 33, Issue 1, 2011, Pages 135-144

  Lu, Christine Y ^a   Law, Michael R ^a,b   Soumerai, Stephen B ^a   Graves, Amy Johnson ^a   LeCates, Robert F ^a   Zhang, Fang ^a   Ross Degnan, Dennis ^a   Adams, Alyce S ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c DIVISION OF RESEARCH   (United States)

Author keywords

Drug expenditure; Drug utilization; Lipid lowering drugs; Medicaid; Prior authorization; Statins

Indexed keywords

ANTILIPEMIC AGENT; ASPARTAME; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; SLO NIACIN; SUCROSE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG COST; DRUG USE; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; LONGITUDINAL STUDY; MALE; MEDICAID; MEDICARE; PRESCRIPTION; UNITED STATES;

COHORT STUDIES; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOLIPIDEMIC AGENTS; INDIANA; LONGITUDINAL STUDIES; MALE; MEDICAID; MEDICARE; MICHIGAN; MIDDLE AGED; ORGANIZATIONAL POLICY; REIMBURSEMENT MECHANISMS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 79952510681     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.012     Document Type: Article

References (28)

1. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2009;119:e182]. Circulation 2009, 119:480-486. American Heart Association Statistics Committee and Stroke Statistics Committee.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
3. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 1999, 282:2340-2346.
4. Vrecer M., Turk S., Drinovec J., Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther 2003, 41:567-577.
5. Lied T.R., Gonzalez J., Taparanskas W., Shukla T. Trends and current drug utilization patterns of Medicaid beneficiaries. Health Care Financ Rev 2006, 27:123-132.
6. Soumerai S.B. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood) 2004, 23:135-146.
7. Catapano A.L. Perspectives on low-density lipoprotein cholesterol goal achievement. Curr Med Res Opin 2009, 25:431-447.
8. Worz C.R., Bottorff M. Treating dyslipidemic patients with lipid-modifying and combination therapies. Pharmacotherapy 2003, 23:625-637.
9. Law M.R., Lu C.Y., Soumerai S.B., et al. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: Results of a longitudinal, population-based study. Clin Ther 2010, 32:729-741. discussion 716.
10. Adams A.S., Zhang F., LeCates R.F., et al. Prior authorization for antidepressants in Medicaid: Effects among disabled dual enrollees. Arch Intern Med 2009, 169:750-756.
11. Wagner A.K., Soumerai S.B., Zhang F., Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002, 27:299-309.
12. Wagner A.K., Soumerai S.B., Zhang F., et al. Effects of state surveillance on new post-hospitalization benzodiazepine use. Int J Qual Health Care 2003, 15:423-431.
13. Consumer Price Index United States Department of Labor, Bureau of Labor Statistics, Accessed October 2009. http://www.bls.gov/cpi/.
14. Lu C.Y., Soumerai S.B., Ross-Degnan D., et al. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Med Care 2010, 48:4-9.
15. Fischer M.A., Schneeweiss S., Avorn J., Solomon D.H. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Eng J Med 2004, 351:2187-2194.
16. Smalley W.E., Griffin M.R., Fought R.L., et al. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med 1995, 332:1612-1617.
17. Delate T., Mager D.E., Sheth J., Motheral B.R. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care 2005, 11:29-36.
18. Law M.R., Ross-Degnan D., Soumerai S.B. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr Serv 2008, 59:540-546.
19. Zhang Y., Adams A.S., Ross-Degnan D., et al. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. Psychiatr Serv 2009, 60:520-527.
20. Soumerai S.B., Zhang F., Ross-Degnan D., et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood) 2008, 27:w185-w195.
21. Schneeweiss S., Patrick A.R., Maclure M., et al. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: A population-based natural experiment. Circulation 2007, 115:2128-2135.
22. Phillips B., Roberts C., Rudolph A.E., et al. Switching statins: The impact on patient outcomes. Br J Cardiol 2007, 14:280-285.
23. Thiebaud P., Patel B.V., Nichol M.B., Berenbeim D.M. The effect of switching on compliance and persistence: The case of statin treatment. Am J Manag Care 2005, 11:670-674.
24. Hess G., Sanders K.N., Hill J., Liu L.Z. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin [published correction appears in Am J Manag Care. 2007;13:432]. Am J Manag Care 2007, 13(Suppl 3):S80-S85.
25. Newhouse J.P. Medical care costs: How much welfare loss?. J Econ Perspect 1992, 6:3-21.
26. Ketcham J.D., Epstein A.J. Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives?. Pharmacoeconomics 2006, 24(Suppl 3):27-40.
27. MacKinnon N.J., Kumar R. Prior authorization programs: A critical review of the literature. J Manag Care Pharm 2001, 7:297-302.
28. Ketcham J.D., Epstein A.J. Medicaid preferred drug lists' costs to physicians. Med Care 2008, 46:9-16.